Skip to main content
. 2022 Mar 15;14(3):643. doi: 10.3390/pharmaceutics14030643

Figure 2.

Figure 2

Results of bioequivalence evaluations, and AUClast ratios with 90% CI between groups A–F in parallel design. To the right of the division line is the group IIV AUClast ratio to compare periods from cross-over design. Log scale was used on y axis.